Treatment of Transthyretin Cardiac Amyloidosis (ATTR-CM)

Transthyretin cardiac amyloidosis (ATTR-CM) represents a specific form of cardiac amyloidosis defined by transthyretin involvement. Stabilization and reduction of transthyretin production are the recognized basis of treatment in this setting.

Clinical Scenario

This protocol is directed at patients with confirmed transthyretin cardiac amyloidosis. The therapeutic focus centers on the transthyretin protein as the primary target of intervention.

Treatment Approach

The central strategy is transthyretin stabilization. An agent in this therapeutic category has demonstrated a reduction in all-cause mortality and cardiovascular hospitalizations, with the most pronounced benefit seen in patients at earlier NYHA functional classes. The complete evidence-based regimen — including selection criteria and the full clinical algorithm — is available via the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehad194

Transthyretin stabilization and reduction of its production are the basis of TTR cardiac amyloidosis treatment.
Tafamidis reduced all-cause mortality and cardiovascular hospitalizations in ATTR, with the largest effect achieved in patients at NYHA functional class I and II.

View source ↗